Effectiveness of an Augmented Reality-Assisted Baduanjin on Multidimensional Frailty Among Older Adults in Long-Term Care Facility: A Three-Arm Randomized Controlled Trial.

J Am Med Dir AssocJul 31, 2026 (epub)
Clinical ResearchGeriatrics

Shiqi Yu, Yi Mao, Jun Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This three-arm randomized controlled trial assessed the impact of augmented reality (AR)-assisted Baduanjin on multidimensional frailty in 117 older adults (average age 75.5 years) in long-term care facilities. The AR group demonstrated significant improvements in frailty compared to controls at 12 weeks (P < .01), along with enhanced physical function and cognitive outcomes.

Key findings

  • The AR group showed greater improvement in frailty compared to controls at 12 weeks (P < .01).
  • Significant effects of time and group were observed for frailty (F = 39.47; P < .01).
  • AR produced superior gains in physical function and Activities of Daily Living Scale compared to video and control groups.
  • Adherence rates were high, with 91% in the AR group and 89% in the video group.

Why it matters

Frailty in older adults is associated with increased care dependence and functional decline. Effective interventions like AR-assisted Baduanjin may enhance health outcomes and quality of life in this vulnerable population.

Source

PubMed · PMID 42537625

Published in J Am Med Dir Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.